Education
About Us
Working with TipRanks
Follow Us
Ardelyx (ARDX)
NASDAQ:ARDX
ARDX Stock Chart & Stats
$5.92
-$0.17(-3.14%)
At close: 4:00 PM EST
$5.92
-$0.17(-3.14%)
Day’s Range― - ―
52-Week Range$3.21 - $6.78
Previous CloseN/A
Volume1.36M
Average Volume (3M)3.81M
Market Cap
$1.44B
Enterprise Value$1.30B
Total Cash (Recent Filing)$242.71M
Total Debt (Recent Filing)$207.61M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Mar 11, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding242,974,300
10 Day Avg. Volume4,939,371
30 Day Avg. Volume3,811,865
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)6.88
Price to Sales (P/S)3.57
P/FCF Ratio-26.03
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue3.26
Enterprise Value/Gross Profit3.64
Enterprise Value/Ebitda-39.93
Forecast
1Y Price Target
$12.11Price Target Upside104.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Market OpportunityUp to 50% of patients with IBS-C fail GCC agonists, leaving a white-space opportunity for Ibsrela as a key treatment option.
Prescription TrendsManagement noted that the beat was driven by record new and repeated prescriptions, with the first couple weeks of this quarter showing an ~60% increase in NRx and TRx over the same period last year.
Revenue GrowthManagement has raised 2025 Ibsrela revenue expectations to $270-$275M, indicating confidence in the product's market performance.
Bears Say
Market AccessMedicare Part D no longer covers XPHOZAH and oral phosphate binders from January 1, 2025.
Medicare CoverageXPHOZAH faces challenges due to the loss of Medicare Part D coverage, impacting its commercial environment and requiring adjustments.
Revenue DeclineThe Y/Y decline in Xphozah revenue was due to the loss of Part D coverage due to oral only phosphate drugs being included in the ESRD 'bundle' on Jan. 1.
Ardelyx News
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $3.21 and its highest was $6.78 in the past 12 months.
What is Ardelyx’s market cap?
Ardelyx’s market cap is $1.44B.
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Mar 11, 2026 which is in 126 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Oct 30, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.058 by $0.058.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is <0.01.
How many shares outstanding does Ardelyx have?
Ardelyx has 242,974,300 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of $0 in its last earnings report, beating expectations of -$0.058. Following the earnings report the stock price went up 20.958%.
Which hedge fund is a major shareholder of Ardelyx?
Currently, no hedge funds are holding shares in ARDX
Ardelyx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.11 (104.56% Upside)
$12.11 (104.56% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 920.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $996.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.79%
12-Months-Change
Fundamentals
Return on Equity
-36.18%
Trailing 12-Months
Asset Growth
32.16%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
ARDX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Ardelyx's strong financial performance, driven by significant growth in IBSRELA and XPHOZAH revenue. The introduction of a new compound, ARDX-10531, marks a positive step in pipeline development. However, challenges remain, particularly in achieving XPHOZAH's long-term revenue goals amidst market disruptions.View all ARDX earnings summariesARDX Stock 12 Month Forecast
Average Price Target
$12.11
▲(104.56% Upside)
Technical Analysis
Vericel
―
Viridian Therapeutics
―
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Ownership Overview
3.36% Insiders
20.82% Mutual Funds
0.02% Other Institutional Investors
63.81% Public Companies and Individual Investors